Thirteen days after Cochrane challenged the promise of anti-amyloid Alzheimer's drugs, Britain has given the argument a closing date.

The National Institute for Health and Care Excellence consultation on lecanemab and donanemab closes Tuesday, with a committee meeting scheduled for June 10. [2] Monday's paper said Day 12 had made reimbursement silence the story. Tuesday makes that silence procedural. Someone, somewhere, is now collecting the arguments that patients, doctors, manufacturers and payers will live with.

Cochrane's review concluded that anti-amyloid monoclonal antibodies probably produce little to no meaningful benefit in cognition or dementia severity at 18 months, while increasing amyloid-related imaging abnormalities such as brain swelling and microbleeds. [1] That finding did not end the scientific fight. It made the policy question unavoidable.

The Pharmaceutical Journal reported the NICE consultation as a reopening of previously rejected Alzheimer's treatments, then separately reported Cochrane's conclusion that amyloid-targeting drugs were probably not effective in a clinically meaningful way. [2][3] The Alzheimer's Society, responding to the review, stressed the complexity of the evidence and the need to consider what families want from treatment. [4]

That patient-centered caution is right. It is also incomplete. Hope is not a reimbursement standard. Desperation is not an evidence hierarchy. A public health system can acknowledge the cruelty of Alzheimer's and still ask whether a drug class offers enough benefit, at enough safety, for enough people, to justify coverage.

The divergence is between proof and process. Mainstream medical coverage still litigates whether Cochrane pooled the right drugs, used the right horizon and weighed newer agents fairly. Health X has moved to the institutional question: if the strongest evidence review says benefit is absent or trivial for many patients, why do payer systems continue as if the premise is unchanged?

NICE at least has a docket. That matters. A consultation forces claims into a record. It asks manufacturers, clinicians, patient advocates and skeptics to translate conviction into submission. The United States has the less legible problem. FDA approval and Medicare payment are not the same decision, and the paper's prior position was that CMS, FDA, Eisai and Lilly had not publicly reconciled the review with the reimbursement lane. That remains true in the available record.

Families need less fog. They are asked to evaluate infusion visits, MRI monitoring, transport, caregiver schedules, adverse-event risk and the possibility of modest slowing. They do not need a slogan saying the drugs are miracles or frauds. They need institutions to state what counts as meaningful benefit and who pays while that meaning is contested.

The NICE calendar helps because it names the next point of responsibility. Tuesday closes consultation. June 10 opens committee review. Those dates do not solve the evidence dispute, but they give patients and clinicians a way to watch the system think.

That is what the American side lacks. A registry can be defended as learning. Conditional coverage can be defended as access under uncertainty. But both defenses require speech. If the registry is designed to answer Cochrane's challenge, say how. If it is not, say that too. Silence leaves the sickest families to perform public-policy triage in private rooms.

The review's critics may be right about some limits. Alzheimer's disease moves slowly. Eighteen months is a hard window. Drug effects can be modest and still meaningful to some families. None of those points excuses an institutional blank. They make transparency more necessary.

Day 13 is therefore not another day in a journal fight. It is the day the British process closes one door and opens a larger question. Evidence has spoken in one register. Access advocates will answer in another. Payers should not pretend they are merely listening. They are deciding who bears risk, cost and hope.

That is why procedure deserves moral weight here. A consultation deadline is not compassion, and a committee meeting is not care. But a named process at least tells families where the argument is happening. The crueler system is one that leaves risk everywhere and responsibility nowhere.

The next honest institution will say not only what it believes about benefit, but how uncertainty should be shared among families, clinics, companies, insurers and payers.

-- NORA WHITFIELD, Chicago